Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
- 1 September 2009
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 10 (10), 943-949
- https://doi.org/10.1016/s1470-2045(09)70232-3
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The ‘GISCAD-alternating schedule’ study findingsEuropean Journal of Cancer, 2009
- The Incidence and Risk of Venous Thromboembolism Associated With Cancer and Nonsurgical Cancer TreatmentCancer Investigation, 2009
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- Impact of clinical trial design and execution-related factors on incidence of thromboembolic events in cancer patients: a systematic review and meta-analysisCurrent Medical Research and Opinion, 2008
- Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patientsCancer, 2007
- Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative studyBMJ, 2006
- Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer PatientsJournal of Clinical Oncology, 2005
- Thromboembolic Events in Gastric Cancer: High Incidence in Patients Receiving Irinotecan- and Bevacizumab-Based TherapyJournal of Clinical Oncology, 2005
- Interim Monitoring of Group Sequential Trials Using Spending Functions for the Type I and Type II Error ProbabilitiesDrug Information Journal, 2001
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancerThe Lancet, 1994